Leading Medical Association Announces Scientific and Clinical Review of Potential Relationship Between Diabetes Ketoacidosis and SGLT2 Inhibitors

Monday, June 29, 2015 4:35 pm EDT

Dateline:

JACKSONVILLE, Fla.
"There are still unanswered questions to answer before we draw any definitive conclusions on the subject, and that is what this conference is designed to do."

JACKSONVILLE, Fla.--(BUSINESS WIRE)--The American Association of Clinical Endocrinologists (AACE), the leading medical organization representing more than 6,000 experts in the care and treatment of diabetes patients, today announced plans to convene a conference of U.S. and international experts to examine the issue of diabetic ketoacidosis (DKA) among patients treated with SGLT2 inhibitors, a class of medications approved for use in adults with type 2 diabetes. AACE will conduct this meeting to provide answers to questions from its membership raised in response to recent case reports and publications on the subject.

The AACE/ACE Scientific and Clinical Review of DKA and The Effects of SGLT2 Inhibitors is scheduled to take place October 24-25, 2015 at the Grand Hyatt DFW in Dallas, TX and will assemble top scientists, diabetes experts and relevant stakeholders in the diabetes care arena to examine available data and provide recommendations for prescribers and patients.

“AACE’s responsibility to its members and their diabetes patients is to conduct a complete, objective and balanced evaluation of the data and investigate any knowledge gaps before issuing our recommendations,” states AACE President George Grunberger, MD, FACP, FACE, “There are still unanswered questions to answer before we draw any definitive conclusions on the subject, and that is what this conference is designed to do.”

About the American Association of Clinical Endocrinologists (AACE)

The American Association of Clinical Endocrinologists (AACE) represents more than 6,000 endocrinologists in the United States and abroad. AACE is the largest association of clinical endocrinologists in the world. The majority of AACE members are certified in Diabetes, Endocrinology and Metabolism and concentrate on the treatment of patients with endocrine and metabolic disorders including diabetes, thyroid disorders, osteoporosis, growth hormone deficiency, cholesterol disorders, hypertension and obesity. Visit our website at www.aace.com.

EDITOR'S NOTE: Interview opportunities are available on this topic. Please contact Mary Green at mgreen@aace.com to schedule an interview.

Contact:

American Association of Clinical Endocrinologists (AACE)
Glenn Sebold, 904-353-7878 ext. 122
gsebold@aace.com